Skip to main content
OpenTrials
Completed

NCT Number: NCT04578509

Evaluation of a Screening Program for SARS-CoV-2 Infection in the General Population Based on the Use of New Detection Approaches or for Diagnostic Orientation on Saliva

The investigators hypothesize that detection of SARS-CoV2 on saliva samples will increase the performance of the screening program compared to the reference strategy (RT-PCR on a nasopharyngeal swab).

Completed

Looking for future studies?

Notify Me

Key information

Sex eligibility

All sexes

Study type

Observational

Primary location

SARS-CoV-2 screening device of Assistance Publique des Hôpitaux de Paris (AP-HP)

Paris, 75001, France

About this study

Containment of the COVID19 pandemic relies on mass screening to allow rapid identification and isolation of cases to break transmission chains. The reference diagnostic method is based on detection of viral genomes by PCR on a nasopharyngeal swab sample (NPS).

However, the pandemic has generated a very high demand causing a shortage of specific swabs and difficulties in the supply of reagents and consumables. Nasopharyngeal sampling requires skilled personnel, and is sometimes poorly accepted by patients. These issues can reduce the quality of sampling and therefore the sensitivity of the test. This strategy also requires sending samples to specialized laboratories, generating a delay in providing results.

New diagnostic approaches on saliva samples are being developed allowing 1) an easier sampling procedure and 2) a diagnostic technique that can be performed in point-of-care.

Previous evaluations suggest that these approaches have a lower sensitivity than the reference strategy (PCR on NPS), around 50 to 90% depending on the technique used.

Despite lower sensitivity compared to the reference strategy, the investigators hypothesize that detection of SARS-CoV2 on saliva samples will improve the performance of the screening program by considerably increasing the number of individuals tested in shorter times.

The main objective of the study is to evaluate, for the detection of SARS-CoV-2 infection, the performance of various alternative virological diagnostic strategies on saliva samples, in comparison with the reference technique (RT-PCR on NPS).

The primary endpoint of the study is positivity of the standard technique (RT-PCR on NPS) for the SARS-CoV-2 virus. The result of the alternative strategies on a saliva sample will be considered as positive or negative according to criteria specific to each of them and compared to the result of the reference technique to estimate their respective sensitivity.

The secondary objectives are to compare the diagnostic performances of RT-PCR on saliva versus RT-PCR on NPS, the diagnostic performances of alternative techniques on saliva versus RT-PCR on saliva, to evaluate the acceptability of the saliva self-sampling and the cost-effectiveness of new diagnostic strategies compared to the reference technique.

The study will include adults and children in whom a NPS is performed for SARS-CoV-2 screening. After informed consent, participants will be asked to provide a saliva sample before nasopharyngeal sampling. Both samples will be analyzed in parallel. The analytical performance of each technique will be assessed, centrally or delocalised, depending on the feasibility of the techniques and according to the advice of the scientific board. The analyzes will be carried out by a team of technicians specifically recruited for the study. All samples collected will be stored in a centralized in a biobank.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adult or child subject able to receive nasopharyngeal swab, regardless of age
  • Subject in whom nasopharyngeal swab is performed for detection of SARS-CoV-2 as part of the screening system managed by APHP
  • Subject or parent not opposed to saliva sampling and data collection as part of this research

Exclusion criteria

  • None

Treatment and study plan

Nasopharyngeal swab

Diagnostic Test

Research of SARS-CoV-2 infection in nasopharyngeal swab by RT-PCR and by antigenic test

Saliva sample

Diagnostic Test

Research of SARS-CoV-2 infection in saliva samples by RT-PCR and by new detection approach

axillary sweat sample

Diagnostic Test

Research of volatile olfactory compounds of SARS-CoV-2 infection by canine detection on axillary sweat.

Data Collection

Other

Demographics, symptoms, medical history, acceptability of specimen, consumption in precedents hours are collected

Primary outcomes

  1. Positivity of RT-PCR on nasopharyngeal swab for the SARS-CoV-2 virus

    Time frame: At diagnosis

    RT-PCR on nasopharyngeal is considered as gold standard

Secondary outcomes

  1. Positivity of RT-PCR on saliva sample for the SARS-CoV-2 virus

    Time frame: At diagnosis

  2. Positivity of new detection approach on saliva sample for the SARS-CoV-2 virus

    Time frame: At diagnosis

  3. Positivity of antigenic test on nasopharyngeal swab for the SARS-CoV-2 virus

    Time frame: At diagnosis

  4. Practicability to samples

    Time frame: At diagnosis

    Number of samples tested in a day for each test

  5. Practicability to premises

    Time frame: At diagnosis

    Quantity of premises required for each test

  6. Practicability to interpretation

    Time frame: At diagnosis

    Feasibly Reading and interpretation For each test

  7. Practicability to render time

    Time frame: At diagnosis

    Render times for each test

  8. IgG Antibody detection in saliva

    Time frame: At diagnosis

    Research of IgG by ELISA and RDT

  9. IgM Antibody detection in saliva

    Time frame: At diagnosis

    Research of IgM by ELISA and RDT

  10. IgA Antibody detection in saliva

    Time frame: At diagnosis

    Research of IgA by ELISA and RDT

  11. Positivity of canine olfactory detection of SARS-CoV-2

    Time frame: At diagnosis

  12. Patient tolerance of the salivary self-sampling

    Time frame: At diagnosis

    Evaluation by questionnaire of the patient tolerance of the salivary self-sampling compared to the nasopharyngeal swab (questions are about pain, discomfort, speed of performance)

  13. Operator tolerance of the salivary self-sampling

    Time frame: At diagnosis

    Evaluation by questionnaire of the operator tolerance of the salivary self-sampling compared to the nasopharyngeal swab (questions is about pain, discomfort, speed of performance)

  14. Cost of each approach

    Time frame: At diagnosis

    Including sampling, transport, technique (consumables, reagents, machine), human resources

Sponsors and collaborators

Lead sponsor

Assistance Publique - Hôpitaux de Paris

Other

Collaborators

  • URC-CIC Paris Descartes Necker Cochin

Registry information

Official study title

Evaluation of a Screening Program for SARS-CoV-2 Infection in the General Population Based on the Use of New Detection Approaches or for Diagnostic Orientation on Saliva (COVID-19)

Acronym: SALICOV

Important dates

Study start
2020
Primary completion
2021
Study completion
2021
First posted
Oct 8, 2020
Registry last updated
Mar 9, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.